Regenxbio Inc. (NASDAQ:RGNX)’s share price shot up 2.9% during trading on Tuesday . The stock traded as high as $12.94 and last traded at $12.62, with a volume of 204,954 shares. The stock had previously closed at $12.27.

Several research firms recently commented on RGNX. Piper Jaffray Cos. set a $25.00 target price on Regenxbio and gave the stock a “buy” rating in a research report on Thursday, August 18th. Zacks Investment Research cut Regenxbio from a “buy” rating to a “hold” rating in a report on Thursday, July 7th. Finally, Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $26.75.

The stock’s market capitalization is $309.91 million. The stock has a 50-day moving average price of $9.92 and a 200-day moving average price of $10.91.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. On average, equities analysts anticipate that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.